Drug Profile
Influenza A vaccines - Takeda
Alternative Names: BLB-750; Cell cultured influenza vaccine H5N1 TAKEDA 1mL; Cell cultured influenza vaccine H5N1 TAKEDA 5ml; Cell cultured influenza vaccine prototype TAKEDA 1mL; Cell cultured influenza vaccine prototype TAKEDA 5ml; Pandemic influenza vaccines - Takeda/National ResilienceLatest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Takeda
- Class Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza A virus H5N1 subtype; Influenza A virus infections
Most Recent Events
- 14 Dec 2017 Takeda initiates enrolment in a post-marketing phase IV trial for Influenza infections (In volunteers) in Japan (NCT03370289)
- 07 Dec 2017 Takeda plans a post-marketing phase IV study of influenza A vaccine in healthy volunteers (JapicCTI-173797)
- 07 Dec 2017 Launched for Influenza-A virus H5N1 subtype (Prevention) in Japan (Parenteral) before December 2017